Search for: "KV Pharmaceutical Company"
Results 41 - 60
of 67
Sorted by Relevance
|
Sort by Date
8 Sep 2011, 6:03 am
That’s how KV Pharmaceutical here in St. [read post]
9 Dec 2011, 12:52 pm
KV PHARMACEUTICAL SETTLES FALSE CLAIMS SUIT FOR $17 MILLION As False Claims Act lawyers, we recently read a news story on a for-profit company that sought reimbursement from the federal government for unapproved medications. [read post]
27 Dec 2011, 9:56 am
” Janssen Pharmaceuticals argued it was “inherently prejudicial” to admit that email into the jury, as if drug companies had special license to lie to juries about deceiving the FDA. [read post]
1 Dec 2009, 9:39 am
KV Pharmaceutical Corp., 2008 WL 2937415 (D.N.J. 2008). [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
27 Mar 2009, 8:00 am
(Intellectual Property Watch) Two final thoughts on big pharma acquisitions (IP finance) Brazil: Patent term cutbacks in Brazil and pharmaceutical pipelines – IP Think Tank podcast 23 March 2009 (IP Think Tank) Brazil: Patent term cutbacks - Lobbying, intellectual property and superior courts (IP Think Tank) Brazil: Patent term extension (PTE) under TRIPs revisited and reviewed by Superior Court of Justice (IP tango) Denmark: Harmonisation in Denmark: Patents covering… [read post]
5 Apr 2011, 6:00 am
KV Pharmaceutical previously had exclusive permission to sell the drug, but after the company set the drug’s price, the FDA raised concerns about its accessibility to low income-women.President Obama delivered a speech about energy, declaring a national goal of reducing oil imports by a third by 2025, compared to a baseline year of 2008. [read post]
2 Mar 2009, 1:47 am
Hat tip to the Courthouse News Service for the KV Pharmaceutical complaint. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent Docs)… [read post]
8 Jul 2012, 7:01 pm
Karst – In a rare lawsuit against FDA involving the Orphan Drug Act of 1983, as amended, K-V Pharmaceutical Company (“KV”) and its wholly-owned subsidiary, Ther-Rx Corporation (“Ther-Rx”), filed a Complaint and a Motion for Temporary Restraining Order and Preliminary Injunction in the U.S. [read post]
18 Mar 2010, 2:30 am
Mylan Pharmaceuticals, Inc. et al. [read post]
29 Jul 2010, 6:24 am
Consumers can be hurt by lax manufacturing practices, as KV Pharmaceutical here in St. [read post]
6 Aug 2007, 4:37 am
KV Pharmaceutical Company, et al. (07/23/2007): multiple suits filed by plaintiffs in various jurisdictions asserting the defendants' filed ANDAs infringe their patents; cases consolidated in Missouri; appeal of grant of summary judgment finding the patents invalid and unenforceable (affirmed-in-part, vacated-in-part, and remanded); discussion of two patents related to a composition used to treat angina, hypertension, and congestive heart failure (U.S. [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
22 Dec 2011, 11:59 am
KV Pharmaceutical Co., 2011 WL 6257466 (E.D. [read post]
1 Apr 2009, 2:07 am
These investors’ liquidity issues continue to give rise to new litigation; for example, I described in recent post (here) the lawsuit that KV Pharmaceuticals filed in late February against Citigroup, in which the company alleged that the illiquidity of its auction rate securities investments was, among other things, forcing the company to lay off workers. [read post]
4 May 2011, 7:52 am
Generic Opioid Products Generic Name Drug Name Applicant/Sponsors Fentanyl Fentanyl Extended Release Transdermal System Actavis Fentanyl Fentanyl Extended Release Transdermal System Lavipharm Labs Fentanyl Fentanyl Extended Release Transdermal System Mylan Technologies Fentanyl Fentanyl Extended Release Transdermal System Teva Pharms Fentanyl Fentanyl Extended Release Transdermal System Watson Methadone … [read post]
